ClinicalTrials.gg
RecruitingNCT07007338Cin-caUpdated May 22, 2026

Calcium Isotope Ratios to Assess Calcium Bone Balance in Dialysis Children Receiving Cinacalcet

An observational study in Children Over 3 Undergoing Dialysis With Secondary Hyperparathyroidism, sponsored by Hospices Civils de Lyon. Recruiting at 7 sites in France. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Hospices Civils de Lyon · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
3 Years to 17 Years
Sex
All
01

Study summary

Managing bone and mineral disorders associated with chronic kidney disease (CKD-MBD) in children is a complex task. Controlling parathyroid hormone (PTH) levels involves adjusting calcium intake, managing hyperphosphatemia, intensive dialysis, and considering specific therapies like active vitamin D analogues and cinacalcet.

Cinacalcet, authorized in Europe since 2017 for children over 3 undergoing dialysis with secondary hyperparathyroidism (SHPT), has shown efficacy in reducing PTH levels. The 2019 guidelines call for its use with caution particularly to avoid hypocalcemia, in children with severe hyperparathyroidism despite optimized conventional treatments.

In adults, cinacalcet has been found to reduce serum PTH, calcium, and phosphate levels, decrease the risk of vascular calcification, and have a positive effect on bone formation. This suggests that cinacalcet may slow the progression of cardiovascular calcifications.

Additionally, Professor Shroff has introduced a non-invasive method for assessing bone calcium status by analyzing stable calcium isotope ratios in blood. This method would allow to determine whether a treatment such as cinacalcet has a positive influence on bone calcium balance, a key element in the management of CKD-MBD.

02

Conditions studied

  • Children Over 3 Undergoing Dialysis With Secondary Hyperparathyroidism

Keywords

  • CKD-MBD
  • children
  • secondary hyperparathyroism
  • Cinacalcet
  • dialysis
03

In context

Chronic Kidney Disease-Mineral and Bone Disorder

74 studies on the registry are indexed under Chronic Kidney Disease-Mineral and Bone Disorder; 21 are open to participants now.

This study's planned enrollment of 20 is below the median of 160 across 37 observational studies indexed under Chronic Kidney Disease-Mineral and Bone Disorder.

Browse Chronic Kidney Disease-Mineral and Bone Disorder studies →

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

This study will involve children above 3 years of age on maintenance dialysis (hemodialysis, hemodiafiltration, peritoneal dialysis) who begin treatment with cinacalcet.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children from 3 to 17 years of age
  • On maintenance dialysis : hemodialysis, hemodiafiltration, peritoneal dialysis
  • Patient who begin treatment with cinacalcet based on the 2019 European guidelines and at the discretion of the treating physician
  • With normal on
  • With total serum calcium >2.40 mmol/L
  • With heamoglobin > 8g/dl
  • Non - opposition from parents/legal guardians

Exclusion criteria

Exclusion Criteria:

  • Children \< 12 kg
  • Persons deprived of their liberty by a judicial or administrative decision
  • Persons under psychiatric care
  • Persons admitted to a health or social institution for purposes other than research
  • Persons not affiliated to a social security scheme or beneficiaries of a similar scheme
  • Persons participating in other interventional research with an exclusion period still in progress at pre-inclusion
  • Patients who received cinacalcet with 3 months prior inclusion
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Children above 3 years of age on maintenance dialysis who begin treatment with cinacalcet

    Children above 3 years of age on maintenance dialysis (hemodialysis, hemodiafiltration, peritoneal dialysis) who begin treatment with cinacalcet because of secondary hyperparathyroism

    Biological: Supplementary blood samples and urines samples

Interventions

  • BiologicalSupplementary blood samples and urines samples

    Supplementary blood and urines samples realised during routine visits

06

What researchers measure

Primary outcomes

  1. value of isotope ratios of calcium (44/42 Ca) in blood

    value of 44/42 Ca ratio in patients at baseline and, three months after cinacalcet treatment

    Time frame: Baseline / 3 months treatment

07

Study locations

7 of 7 sites recruiting
  • Service de Pédiatrie CHU de Bordeaux
    Bordeaux, 33000, France
    Recruiting
    • MADDEN Iona, MD · Contact
  • Hôpital Femme Mère Enfant
    Bron, 69500, France
    Recruiting
  • Service de pédiatrie multidisciplinaire CHU de Montpellier
    Montpellier, 34295, France
    Recruiting
  • Unité de néphrologie pédiatrique, Hôpital Archet 2, CHU de Nice
    Nice, 06202, France
    Recruiting
  • Service de Néphrologie pédiatrique Hôpital Necker Enfants Malades
    Paris, 75012, France
    Recruiting
  • Service de Néphrologie - Transplantation - Hémodialyse pédiatrique Hôpital Robert Debré
    Paris, 75019, France
    Recruiting
  • Service de pédiatrie 1 CHU Hautepierre
    Strasbourg, 67000, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Aug 2028, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2025
First posted
Jun 5, 2025
StartActual
Apr 29, 2026
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07007338
Responsible party
Sponsor
First posted
Jun 5, 2025
Start date
Apr 29, 2026
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
May 22, 2026

Study contacts

BACCHETTA Justine, MD
Contact
Justine.bacchetta@chu-lyon.fr
0033427856178
FLAMMIER Sacha, MD
Contact
Sacha.flammier@chu-lyon.fr
0033472681349
BACCHETTA Justine, MD
principal investigator · Hospices Civils de Lyon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion